 |
|
|
| |
LEDIPASVIR/SOFOSBUVIR SINGLE-TABLET REGIMEN FOR CHRONIC HEPATITS C (CHC) INFECTION:
INSIGHTS FROM A WORK PRODUCTIVITY ECONOMIC MODEL
|
| |
| |
"At baseline, the rates of presenteeism and absenteeism among GT1 CHC patients are 7.83% and 2.57%. As a result, not treating CHC patients is expected to result in $7.11 billion of lost productivity costs annually.
· LDV/SOF treatment resulted in 93.2% of USA patients achieving an SVR12 which was associated with an increase in work productivity by 41% from baseline, an expected economic gain of $2.7 billion per year. These gains were only due to improvements in presenteeism 12 weeks after treatment discontinuation (Figure 1, Table 2). It was assumed that the changes in presenteeism and absenteeism were equally weighted in cirrhotics and non-cirrhotics."
"In the ION trials, LDV/SOF improved presenteeism by 55% from baseline (Figure 1). Given productivity loss data were only captured 12 weeks post-treatment, in a sensitivity analysis, the benefit of LDV/SOF over baseline on presenteeism was varied from 60% to 90% to account for potential longer-term presenteeism benefits
post-SVR12.
- Here, savings were expected to range from $2.9 billion per year with a 60% presenteeism improvement, to $4.4 billion per year with a 90% presenteeism improvement (Figure 3).
· A further sensitivity analysis looked at the specific productivity loss benefit conferred by LDV/SOF in patients stratified by cirrhosis. (Figure 4)
- In non-cirrhotic patients, productivity loss improvements resulting from treatment with LDV/SOF were expected to result in savings of $2.1 billion per year relative to no treatment.
- In cirrhotic patients, productivity loss improvements resulting from treatment with LDV/SOF were expected to result in savings of $0.6 billion per year relative to no treatment."
Reported by Jules Levin
AASLD Nov 7-11 2014 Boston
Zobair Younossi1,4, Yushan Jiang2, Nathaniel J. Smith2, Maria Stepanova3, Rachel Beckerman2
1.Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA
2.CBPartners, New York, NY
3. CLDQ LLC, Washington, DC
4.Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA
|
| |
|
|
|
|
|
